Merck's adenosine A2A antagonist was one of the more novel candidates for Parkinson's in Phase 3. Today is failed. This just highlights how special pimavanserin really is. Merck most certainly knows of Acadia...
Well, I think the press release would make you feel better because Merck went on to discuss just how tough Parkinson's is to treat. I walked away with an even bigger appreciation for what Acadia has done. It's so rare to see a true breakthrough medication. I know quite a bit about the 5HT2A mechanism that pimavanserin works through and there are reasons (neurological) to ponder whether it might actually have a positive impact on other disease symptoms because of it's method of action. It has been postulated that blocking 5HT2A results in a net increase of dopamine in certain brain regions. It should be mentioned that the adenosine A2A program also works by increasing dopamine in certain brain regions, but hitting the right regions/combinations is very tough.
Pimavanserin is simply starting to look special. I'm really looking forward to more data releases as it may be that the story is more exciting than we realize. It's possible that PDP is just the beginning in Parkinson's disease. Also, the ADP side is just crazy. I've been investing for so long now and I still can't wrap my head around the potential opportunity here.
So yes, I get why you were feeling bad for the patients and I always feel that way too. However, it's all just making me see pimavanserin as being that much more significant. Breakthrough....that's such a rare word....it hasn't happened in CNS in many years.